Asset profile
BI 765049
Monoclonal antibody
Evidence outlook · lead readout
NCT04752215 · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04752215: This was an open-label, non-randomized dose-escalation study with no placebo or standard-of-care control group, designed to find a tolerable dose rather than to test whether the drug worked; results have not yet been reported.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.